Phase 1 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC), confirmed by a biopsy, lab test, or — if you have liver scarring (cirrhosis) — by specific medical guidelines
- You have already tried at least one type of systemic treatment (such as drug therapy given throughout the body) for liver cancer that cannot be removed by surgery or has spread to other parts of the body
- Your tumor has a specific genetic change in a pathway called the "WNT pathway" (a test would be needed to confirm this)
- Your liver is functioning at a certain level, rated as Child-Pugh class A or B7 (a measure of liver health — confirm with trial site if unsure of your score)
Who may not be able to join:
- You have a specific uncommon type of liver cancer, including fibrolamellar HCC, sarcomatoid HCC, or a mixed type involving the bile ducts
- You have cancer that has spread outside the liver and is causing noticeable symptoms
- You have received any cancer treatment or experimental drug within 3 weeks before the first dose of the trial medication
Important: This list may not be complete, as additional eligibility requirements exist that are not listed here. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Alnylam Pharmaceuticals
Phone: 1-877-ALNYLAM
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of Adverse Events (AEs); Severity of AEs; Dose Escalation: Occurrence of Dose-limiting Toxicities (DLTs); Dose Expansion: Antitumor Activity as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.